Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 5, 2017, Pages 744-748

  Kramer, Caroline K ^a,b   Zinman, Bernard ^a,b,c   Choi, Haysook ^a   Connelly, Philip W ^b,d   Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

GIP; GLP 1; LIBRA; liraglutide; type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HORMONE RELEASE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; ADULT; AGONISTS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENTEROENDOCRINE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPOGLYCEMIA; METABOLISM; PANCREAS ISLET BETA CELL; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR;

ADULT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENTEROENDOCRINE CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; INSULIN-SECRETING CELLS; LIRAGLUTIDE; TIME FACTORS;

EID: 85012887871     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12858     Document Type: Article

References (17)

1. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab. 2012;14(suppl 3):161-166.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
3. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-18.
4. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014;37:3270-3278.
5. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care. 2014;37:1116-1123.
6. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of beta-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab. 2013;305:E1398-E1407.
7. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab. 2010;12:909-915.
8. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab. 2010;12:65-71.
9. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281(1):E155-E161.
10. Lin J, Hodge RJ, O'Connor-Semmes RL, Nunez DJ. GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects. Diabetes Obes Metab. 2015;17(10):1007-1110.
11. Smits MM, Bunck MC, Diamant M, et al. Effect of 3 years of treatment with exenatide on postprandial glucagon levels. Diabetes Care. 2016;39(3):e42-e43.
12. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001;25:1206-1214.
13. Rask E, Olsson T, Soderberg S, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24:1640-1645.
14. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38:916-919.
15. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7–36) amide secretion by circulating non-esterified fatty acids. Clin Sci. 1999;96:335-342.
16. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706-2713.
17. Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA Trial. J Clin Endocrinol Metab. 2015;100(10):3702-3709.